Release Date: December 9, 2024
Expiration Date: December 9, 2025
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in myasthenia gravis. In this educational program, these experts discuss the supporting data and rationale underpinning best management practices for managing pregnant women and children with myasthenia gravis. The format employs a case-based approach to illustrate real-world patient encounters that require astute and timely clinical decision-making.
This educational activity is an archive of the live symposium held on November 20, 2024.
Target Audience
This educational activity is directed toward neuromuscular disease specialists, neurologists, specialty nurse practitioners, specialty physician assistants, nurses, and other HCPs involved in the care of patients with generalized myasthenia gravis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review treatment challenges for patients from special populations with myasthenia gravis
- Assess emerging data on targeted therapies for myasthenia gravis in specific populations
- Formulate individualized multidisciplinary management plans for myasthenia gravis in patients from specific populations
John Brandsema, MD
Child Neurologist
Children’s Hospital of Philadelphia
Associate Professor of Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
Disclosures: Consultant: AveXis/Novartis; Biogen; Dyne Therapeutics; Edgewise Therapeutics, Inc; FibroGen, Inc; Genentech; Momenta/Janssen; NS Pharma, Inc; Pfizer Inc; PTC Therapeutics, Inc; Sarepta Therapeutics, Inc; Scholar Rock Holding Corporation; Takeda. Site Investigator for research studies: Alexion Pharmaceuticals, Inc; Astellas, AveXis/Novartis, Biogen Inc; Biohaven; Dyne Therapeutics; FibroGen, Inc; Genentech; ML Bio Solutions; Pfizer Inc; PTC Therapeutics, Inc; Sarepta Therapeutics, Inc; Scholar Rock Holding Corporation
Neelam Goyal, MD
Clinical Associate Professor of Neurology and Neurological Sciences
Division of Neuromuscular Medicine
Interim Vice Chair; Diversity, Equity, and Inclusion; Neurology Department
Well-Being Director, Neurology Department
Stanford University Hospital
Palo Alto, CA
Disclosures: Grant/Research Support: Argenx. Consultant: Alexion Pharmaceuticals, Inc; Amgen, Argenx; Janssen; Novartis; UCB. Grant Support: Amgen; Argenx; Alexion Pharmaceuticals, Inc; Janssen; Novartis; UCB
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here